Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
0 0%
1 Year
-99.69%
2 Year
-99.91%
Key data
Stock price
$0.11
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.00 - $0.64
52 WEEK CHANGE
-$99.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
Company detail
CEO: Mei M. Hu
Region: US
Website: vaxxinity.com
Employees: 90
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
Region: US
Website: vaxxinity.com
Employees: 90
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
Vaxxinity, Inc. focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company is developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial. It is also developing an anti-tau product candidate for various neurodegenerative conditions, including AD.
Recent news
